Nasdaq

Milestone Pharmaceuticals Announces PDUFA Date for CARDAMYST™ Nasal Spray and Plans for Phase 3 Study in AFib-RVR

The PDUFA date for CARDAMYST™ is set for March 27, 2025, indicating a lengthy approval timeline that could delay commercialization and revenue generation for the company. The reliance on the FDA's ...
WNCT

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

MONTREAL and CHARLOTTE, N.C., Nov. 11, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and ...
KRQE Blogs

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 ...
WKRG

Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

- Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes - Data featured in an oral ...
KHON2

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

MONTREAL and CHARLOTTE, N.C., May 8, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ...
Nasdaq

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...
ksn.com

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone's website at www.milestonepharma.com. To access the live call by phone, ...